Agios Pharmaceuticals, Inc.
AGIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001439222
In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Agios Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 165 | 1 | 153 | −11 |
| Shares | 58.9M | 24.8K | 59.4M | +535.9K (+0.9%) |
| Value | $1.36B | $569.6K | $1.68B | +$325.2M (+24.0%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Prudential Financial Inc | 112,852 | $3.20M | 0.00% |
| International Biotechnology Trust PLC | 24,000 | $679.7K | 0.21% |
| Graham Capital Management, L.P. | 16,958 | $480.3K | 0.02% |
| AQR Capital Management LLC | 7,717 | $217.3K | 0.00% |
| XTX Topco Ltd | 7,563 | $214.2K | 0.04% |
| Headlands Technologies LLC | 6,884 | $195.0K | 0.06% |
| C M Bidwell & Associates Ltd | 6,345 | $179.7K | 0.13% |
| Versant Capital Management, Inc | 64 | $1.81K | 0.00% |
| Parallel Advisors, LLC | 23 | $651 | 0.00% |
| Gradient Investments LLC | 22 | $623 | 0.00% |
| Allworth Financial LP | 20 | $567 | 0.00% |
Sold out (22)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Integral Health Asset Management, LLC | 213,000 | $4.89M |
| Bank of Montreal | 134,396 | $3.12M |
| Victory Capital Management Inc | 52,670 | $1.21M |
| Duality Advisers, LP | 24,659 | $566.4K |
| Trexquant Investment LP | 24,613 | $565.4K |
| Winton Group Ltd | 23,865 | $548.2K |
| Hennion & Walsh Asset Management, Inc. | 22,525 | $517.0K |
| Panagora Asset Management Inc | 20,052 | $460.6K |
| Candriam Luxembourg S.C.A. | 20,160 | $426.2K |
| Tudor Investment Corp Et Al | 14,755 | $339.0K |
| Squarepoint Ops LLC | 10,956 | $251.7K |
| Bayesian Capital Management, LP | 10,802 | $248.1K |
| HRT Financial LP | 9,817 | $225.0K |
| SG Americas Securities, LLC | 7,789 | $179.0K |
| Caption Management, LLC | 4,086 | $93.9K |
| Aquatic Capital Management LLC | 1,100 | $25.0K |
| Advisory Services Network, LLC | 350 | $8.04K |
| Baillie Gifford & Co | 186 | $4.27K |
| TCI Wealth Advisors, Inc. | 137 | $3.15K |
| EverSource Wealth Advisors, LLC | 56 | $1.29K |
| Schubert & Co | 27 | $621 |
| Steward Financial Group LLC | 9 | $0 |
Not filed for Q2 2023 yet (1)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| ETF Managers Group, LLC | 24,797 | $569.6K |